Hereditary hematologic malignancies: a Canadian perspective
Canadian Hematology Today · 2022
DOI: 10.58931/cht.2022.1319 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Hematology Today, 2022. Verfasst von Amy M. Trottier. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
When a patient is newly diagnosed with a malignancy, two common questions are often asked: 1) why did I get this cancer and 2) are my children or other family members at risk? In the case of hematologic malignancies, the standard response has been that the cause is unknown and family members are not at increased risk. However, hereditary predisposition to hematologic malignancies, especially myeloid malignancies, is becoming increasingly recognized, necessitating a change to this dogma. Hereditary hematologic malignancies are not as rare as previously believed, with an ever-increasing number of predisposition genes and alleles being discovered. Since the initial discovery of familial platelet disorder with associated myeloid malignancy (FPDMM) due to deleterious germline variants in RUNX1 in 1999, the list of predisposition genes, such as CEBPA, DDX41, ETV6, GATA2, and others continues to grow.
Zitieren
APA
Trottier, A. M. (2022). Hereditary hematologic malignancies: a Canadian perspective. Canadian Hematology Today. https://doi.org/10.58931/cht.2022.1319
Vancouver
Trottier AM. Hereditary hematologic malignancies: a Canadian perspective. Canadian Hematology Today. 2022. doi:10.58931/cht.2022.1319
BibTeX
@article{Trottier2022,
author = {Trottier, Amy M.},
title = {Hereditary hematologic malignancies: a Canadian perspective},
journal = {Canadian Hematology Today},
year = {2022},
doi = {10.58931/cht.2022.1319}
}
EUVIMED